Cardiac safety profile of prolonged (≥6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies

Gynecologic Oncology

Volumn 94, Issue 1, 2004, Pages 147-151

  Uyar, Denise ^a   Kulp, Barbara ^a   Peterson, Gertrude ^a   Zanotti, Kristine ^a   Markman, Maurie ^a   Belinson, Jerome ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Doxorubicin; Gynecologic malignancy; Toxicity

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; FAMOTIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INFUSION; DRUG SAFETY; ENDOMETRIUM CANCER; ERYTHEMA; FEMALE; GYNECOLOGIC CANCER; HEALTH CENTER; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MEDICAL ASSESSMENT; MEDICAL RECORD; NAUSEA; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STOMATITIS; SYMPTOM; TIME; TOXICITY;

EID: 3242703387     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.024     Document Type: Article

References (38)

1. Gordon AN, Granai O, Rose PG, Hainsworth J, Lopez A, Weissman C, et al. Phase 2 study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000;18(17):3093- 100.
2. Markman M, Kennedy A,Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000;78:369- 72.
3. Escobar P, Markman M, Zanotti K, Webster K, Belinson J. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol 2003;129(11):651- 4.
4. Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001;81:206- 12.
5. Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase 2 trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002;20(9):2360- 4.
6. Muggia FM, Hainsworth, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15(3):987- 93.
7. Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M. Liposomal doxorubicin in ovarian, peritoneal and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 2001;82:323-8.
8. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety 2001;24(12):903- 20.
9. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: a rationale for use in solid tumors. Drugs 1997;54(Suppl. 4):15- 21.
10. Allen TM. Liposomes. Drugs 1997;54(Suppl 4):8- 14.
11. 2. Ann Oncol 2000;11:1029-33.
12. Wigler N, O'Brien M, Rosso R, et al. Reduced cardiotoxicity and comparable efficacy in phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Poster presented at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 18-21; 2002.
13. Berry G, Billingham M, Aderman E, Richardson P, Torti F, Lum B, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9:711 -6.
14. Dezube, B.J. Safety assessment: Doxil ( doxorubicin HCl liposome injection) in refractory AIDS-realted Kaposi's sarcoma. Doxil clinical series, vol. 1, No. 2. SEQUUS Pharmaceuticals, Inc., Menlo Park, CA, USA.
15. Von Hoff DD, Layard MW, Basa P, Davis H, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
16. LeFrak EA, Pitha J, Rosenheim S, Gottleib JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302- 14.
17. Minow RA, Benjamin RS, Lee RT, Gottleib JA. Adriamycin cardiomyopathy - risk factors. Cancer 1977;39:1397- 402.
18. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988;48(1):4766- 9.
19. Jackson JA, Reeves JP, Muntz KH, Kruk D, Prough RA,Willerson JT, et al. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol 1984;117(1):140-53.
20. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety 2000;22(4):263 -302.
21. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979;63:827- 34.
22. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993;19:197-228.
23. Hortobagyi G.N. Anthracyclines in the treatment of cancer: an overview. Drugs. 54(Suppl 4):1997;1-7
24. Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982;9(1):23- 33.
25. Schwartz RG, McKenzie WB, Alexander J, Sager P, d'Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109- 17.
26. Paphadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991;88(24):11460- 4.
27. Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer 2001;91(1):90 -100.
28. Goram AL, Richmond PL. Pegylated liposomal doxorubicin: tolerability and toxicity. Pharmacotherapy 2001;21(6):751- 63.
29. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing N, Lotem M, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89(5):1037-47.
30. Opravil M, Tomlinson D, Bogner JR. Caelyx (Doxil liposomal doxorubicin) is tolerated well long-term at high cumulative dose in AIDS-related Kaposi's sarcoma (AIDS-KS) patients: a meta analysis of 1716 patients. Abstr Proc A Soc Clin Oncol, vol. 17; 1998. p. 66.
31. Bristow MR. Anthracycline cardiotoxicity. In: Bristow MR, editor. Drug Induced Heart Disease. New York: Elsevier; 1980. p. 191- 215.
32. Druck MN, Gulenchyn KY, Evans WK, Gotlieb A, Srigley JR, Bar-Shlomo BZ, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 1984;53:1667- 74.
33. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996;53:461-70.
34. Wackers FJ, Berger HJ, Johnstone DE, Goldman L, Rduto LA, Langou RA, et al. Multiple gated cardiac blood pool imaging for left ventricular ejection fraction: validation of the technique and assessment of variability. Am J Cardiol 1979;43:1159.
35. Nousiainen T, Vanninen E, Jantunen E, Remes J, Ritanen E, Vuolteenaho O, et al. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. Clin Sci 2001;101:601-7.
36. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002;4:235 - 42.
37. Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000;104(4):158- 63.
38. Suter TM, Meier B. Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel? Ann Oncol 2002;13:647-9.